Personal cell therapy for interstitial cystitis with autologous stromal vascular fraction stem cells

Lander, Elliot B.; Berman, Mark; See, Jackie R.

doi:10.1177/1756287219868590

Cited by 7 publications

(14 citation statements)

References 30 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Ustem kit is a commercial product designed to simplify the separation process. The SVF contain stem cells and cytokines, which are associated with regenerative, antinociceptive, immunomodulatory, and anti-inflammatory effects [10]. Thus, the SVF has several advantages over pure ADSCs, as the SVF has a distinct and heterogeneous cellular composition compared to that of MSCs, The SVF has demonstrated superior therapeutic results in several preclinical studies [29][30][31][32].…”

Section: Xiao Et Al Analyzed the Effects Of Bone Marrow-derivedmentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy and Safety of a Human Perirenal Adipose Tissue-Derived Stromal Vascular Fraction in an Interstitial Cystitis Rat Model

Lee

Chun

et al. 2023

Tissue Eng Regen Med

View full text Add to dashboard Cite

Background: Interstitial cystitis (IC) is a chronic and intractable disease that can severely deteriorate patients’ quality of life. Recently, stem cell therapy has been introduced as a promising alternative treatment for IC in animal models. We aimed to verify the efficacy and safety of the human perirenal adipose tissue-derived stromal vascular fraction (SVF) in an IC rat model. Methods: From eight-week-old female rats, an IC rat model was established by subcutaneous injection of 200 μg of uroplakin3A. The SVF was injected into the bladder submucosal layer of IC rats, and pain scale analysis, awakening cytometry, and histological and gene analyses of the bladder were performed. For the in vivo safety analysis, genomic DNA purification and histological analysis were also performed to check tumorigenicity and thrombus formation. Results: The mean pain scores in the SVF 20 μl group were significantly lower on days 7 and 14 than those in the control group, and bladder intercontraction intervals were significantly improved in the SVF groups in a dose-dependent manner. Regeneration of the bladder epithelium, basement membrane, and lamina propria was observed in the SVF group. In the SVF groups, however, bladder fibrosis and the expression of inflammatory markers were not significantly improved compared to those in the control group. Conclusion: This study demonstrated that a perirenal adipose tissue-derived SVF is a promising alternative for the management of IC in terms of improving bladder pain and overactivity.

show abstract

Section: Xiao Et Al Analyzed the Effects Of Bone Marrow-derivedmentioning

confidence: 99%

“…Currently, an SVF is usually procured and isolated from subcutaneous adipose tissue via liposuction [ 10 ]. More recently, perirenal adipose tissue has been proposed as a potential cell source for regenerative medicine [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

The Efficacy and Safety of a Human Perirenal Adipose Tissue-Derived Stromal Vascular Fraction in an Interstitial Cystitis Rat Model

Lee

Chun

et al. 2023

Tissue Eng Regen Med

View full text Add to dashboard Cite

show abstract

“…To date, only 1 clinical trial has assessed the efficacy of stem cells for IC/BPS. In 2019, Lander et al [47] investigated the effect of combined intravenous and local injections of autologous stromal vascular fraction (SVF) into the pelvic floor in 91 women and 18 men with IC/BPS. Although that study demonstrated that SVF, as an autologous personalized regenerative strategy, showed good safety and efficacy and may have the potential to alleviate IC/BPS, the major limitations were the lack of a control group, inconsistent transplantation cell number, inconsistent cell injection routes in male patients, lack of information on the molecular mechanisms of SVF therapy, and the absence of long-term data.…”

Section: Clinical Trialsmentioning

confidence: 99%

New Frontiers or the Treatment of Interstitial Cystitis/Bladder Pain Syndrome - Focused on Stem Cells, Platelet-Rich Plasma, and Low-Energy Shock Wave

et al. 2020

View full text Add to dashboard Cite

Interstitial cystitis/bladder pain syndrome (IC/BPS), which is characterized by bladder pain and irritative voiding symptoms, is a frustrating disease without effective treatment. The cause is still largely not understood, although urothelium ischemia/hypoxia, apoptosis, denudation, and infiltration of inflammatory cells are common histopathological findings. The current uncertainty regarding the etiology and pathology of IC/BPS has a negative impact on its timely and successful treatment; therefore, the development of new treatment modalities is urgently needed. Herein, we present advances in our knowledge on this topic and review the potential application of regenerative medicine for the treatment of IC/BPS. This article provides information on the basic characteristics and clinical evidence of stem cells, platelet-rich plasma (PRP), and low-energy shock waves (LESWs) based on a literature review with a search strategy for articles related to IC/BPS, stem cells, PRP, and LESW published in MEDLINE and PubMed. Stem cells, PRP, and LESW, which modulate inflammatory processes and promote tissue repair, have been proven to improve bladder regeneration, relieve bladder pain, inhibit bladder inflammation, and increase bladder capacity in some preclinical studies. However, clinical studies are still in their infancy. Based on the mechanisms of action of stem cells, PRP, and LESW documented in many preclinical studies, the potential applications of regenerative medicine for the treatment of IC/BPS is an emerging frontier of interest. However, solid evidence from clinical studies remains to be obtained.

show abstract

“…Recently, the potential applications of regenerative medicine, such as platelet-rich plasma (PRP) and stem cells, have been shown to be beneficial to treatment of IC/BPS in some preclinical and few clinical studies. 9–12 PRP, which contains several growth factors and signal proteins released by actively degranulated platelets, acts on available cells to begin the tissue repair and regeneration processes. 9,10 Nanofat, which is a stromal vascular fraction (SVF) obtained from mechanical emulsification and filtration of adipose tissue and contains a heterogeneous population of stem/progenitor cells and extracellular matrix, is a therapeutic paradigm in regenerative medicine.…”

Section: Introductionmentioning

confidence: 99%

Improved symptoms and signs of refractory interstitial cystitis in women after intravesical Nanofat plus platelet-rich plasma grafting: A pilot study

Hung

Tsai

Ying

et al. 2022

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Interstitial cystitis/bladder pain syndrome (IC/BPS) is characterized by bladder pain accompanied by irritative urinary symptoms, and typical cystoscopic and histological features. In this pilot study, we assessed the impact of lesion-targeted bladder injection therapy using a biocellular regenerative medicine on patients with refractory IC/BPS. The medicine, which was an autologous emulsified fat (Nanofat) and platelet-rich plasma (PRP) combination, was prepared intraoperatively. Six patients (aged 40-54 years), who completed a standard protocol of four consecutive treatments at 3-month intervals, were followed up at 6 months postoperatively. All patients (100%) reported marked (+3; +3 ~ −3) improvement of their overall bladder conditions. Mean bladder pain (from 8.2 to 1.7; range: 0 ~ 10), IC-related symptoms (from 18.5 to 5.7; range: 0 ~ 20), and bother (from 14.8 to 3.8; range: 0 ~ 16) improved significantly (p < 0.01). The normalization of bladder mucosal morphology with treatments was remarkable under cystoscopic examination, and no significant adverse events were found. The cultured mesenchymal stem cells from Nanofat samples of the six patients were verified in vitro. Our preliminary results suggest novel intravesical therapy with autologous Nanofat plus PRP grafting is safe and effective for refractory IC/BPS. Surgical efficacy might be attributed to an in vivo tissue engineering process.

show abstract

Personal cell therapy for interstitial cystitis with autologous stromal vascular fraction stem cells

Cited by 7 publications

References 30 publications

The Efficacy and Safety of a Human Perirenal Adipose Tissue-Derived Stromal Vascular Fraction in an Interstitial Cystitis Rat Model

The Efficacy and Safety of a Human Perirenal Adipose Tissue-Derived Stromal Vascular Fraction in an Interstitial Cystitis Rat Model

New Frontiers or the Treatment of Interstitial Cystitis/Bladder Pain Syndrome - Focused on Stem Cells, Platelet-Rich Plasma, and Low-Energy Shock Wave

Improved symptoms and signs of refractory interstitial cystitis in women after intravesical Nanofat plus platelet-rich plasma grafting: A pilot study

Contact Info

Product

Resources

About